CytRx wishes on STAR-1 in hopes FDA will accelerate tamibarotene
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CytRx is "aggressively working to achieve our goal" of completing the pivotal Phase II STAR-1 trial of oral tamibarotene for third-line treatment of acute promyelocytic leukemia by year-end, the company says June 29. The effort "may include acceleration of the trial through a negotiation with the FDA regarding the total number of patients ultimately enrolled." CytRx has been taking advantage of FDA programs to speed development of drugs for high-need settings, like APL; according to the company, approximately 1,500 patients are diagnosed with the rare cancer annually in the U.S. Tamibarotene, which would be the first approval for APL, has orphan status and fast-track status for relapsed or refractory APL, and the open-label, non-randomized STAR-1 trial is being conducted under a Special Protocol Assessment. The pivotal trial has enrolled 11 patients to date, and five of the patients have achieved a morphologic leukemia-free state, when no leukemia cells can be found in bone marrow, the company reports. MLFS is one of several criteria comprising the primary endpoint of durable complete response
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.